Please contact our sales representative to learn more information about this reagents.
Background
Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC. This drug was developed by Eli Lilly & Company.